Retatrutide hits threeGIP, GLP-1, and glucagonsimultaneously
Generic and biosimilar timeline The pharmaceutical patent landscape suggests that generic and biosimilar versions of current GLP-1 medications will eventually enter the market, though not immediately
While buccal absorption is less efficient than sublingual, it is still better than sending the compound straight to the stomach
2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)